Pieris' Series C Round

Pieris raised a round of funding on November 27, 2014. Investors include Ally Bridge Group.

Pieris is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin technology to create differentiated drugs that are safer and more effective than conventional approa…

Articles about Pieris' Series C Round: